Denali Therapeutics
DNLI
216 hedge funds and large institutions have $4.59B invested in Denali Therapeutics in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 78 increasing their positions, 69 reducing their positions, and 26 closing their positions.
77% more call options, than puts
Call options by funds: $8.56M | Put options by funds: $4.85M
58% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 26
13% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 69
6% more funds holding
Funds holding: 204 → 216 (+12)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
7.4% less ownership
Funds ownership: 73.91% → 66.51% (-7.4%)
25% less capital invested
Capital invested by funds: $6.13B → $4.59B (-$1.53B)
Top Buyers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$53.9M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$37.2M |
| 3 |
CC
Casdin Capital
New York
|
+$20.1M |
| 4 |
Renaissance Technologies
New York
|
+$17.8M |
| 5 |
Morgan Stanley
New York
|
+$16.2M |
Top Sellers
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
-$634M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$55.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$27.2M |
| 4 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
-$27.1M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$17.3M |
DNLI Hedge Fund Activity: Q1 2021 in Review
216 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2021, worth a combined $4.59B — down 25% from $6.13B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new DNLI positions and 26 closed out — a net gain of 15 holders — while 78 added to existing stakes and 69 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $53.9M. The largest seller was Crestline Management, cutting an estimated $634M.
- 216 institutional investors held Denali Therapeutics (DNLI) as of Q1 2021, up from 204 in Q4 2020.
- Funds reported $4.59B of Denali Therapeutics stock for Q1 2021, down 25% quarter-over-quarter.
- 41 funds opened new Denali Therapeutics positions in Q1 2021 and 26 closed out, a net change of +15 holders.
- The largest Denali Therapeutics buyer in Q1 2021 was Baillie Gifford & Co, an estimated $53.9M added.
- The largest Denali Therapeutics seller in Q1 2021 was Crestline Management, an estimated $634M sold.
Based on aggregated 13F filings for Q1 2021.